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MitophagyThe G2019S leucine-rich repeat kinase 2 (LRRK2) mutation is the most common cause of genetic Parkinson's
disease (PD). However, the molecular mechanism underlying LRRK2 G2019S-induced cellular pathology is
poorly understood. Here, we demonstrated that LRRK2 G2019S bound to and phosphorylated Bcl-2, a
mitochondrial anti-apoptotic protein, at Threonine 56. Either stable expression of Bcl-2 or transient expression
of a Bcl-2 phosphor mutant (Bcl-2T56A) abolished LRRK2 G2019S-induced mitochondrial depolarization and
autophagy. Together, our ﬁndings reveal a previously unidentiﬁed target of LRRK2 G2019S, showing that Bcl-2
serves as a point of crosstalk between LRRK2 G2019S-mediated mitochondrial disorder and dysregulation of
autophagy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is one of themost common neurodegener-
ative disorders characterized by progressive and substantial loss of
dopaminergic neurons in the substantia nigra [1,2]. Various genetic
mutations have been detected in PD; G2019S mutation of the Leucine
Rich Repeat Kinase 2 (LRRK2) gene is the most common prevalent
mutation in either genetic or sporadic PD [3–7]. LRRK2 is a large multi-
domain protein with a conserved serine–threonine kinase mitogen-
activated protein kinase kinase kinase (MAPKKK) domain, a Roc GTPase
domain and potential protein–protein interaction regions (leucine-rich
repeat and WD40 domains) [8–10]. The G2019S mutant is associated
with LRRK2 auto-phosphorylation, increased kinase activity and neuro-
toxicity [11]. Several recent lines of evidence have shown that the
LRRK2 G2019S mutant causes mitochondrial dysfunction and aberrant
autophagy in ﬁbroblasts from PD patients with the mutation [12–16],
in dopaminergic neurons derived from induced pluripotent stem cells
of PD patients [17], and in transgenic mice in which a human LRRK2
G2019S mutant was expressed [18]. However, the signal that regulates
LRRK2 G2019S-induced mitochondrial dysregulation and abnormal
autophagy in the context of PD is poorly understood.and Biophysics, Case Western
e, E516, Cleveland, OH 44106-
.Bcl-2, a well-known mitochondrial anti-apoptotic factor, maintains
the mitochondrial membrane potential (MMP) and mitochondrial in-
tegrity [19–23]. Direct binding of Bcl-2 to Beclin-1 inhibits the formation
of Beclin-1/Vps34 complex and subsequent autophagosome formation
[24,25]. Thus, Bcl-2 has also been considered as a physiological inhibitor
of Beclin-1-dependent autophagy [24,25]. Therefore, Bcl-2 functions
both as a pro-survival and anti-autophagic regulator.
In the present study, we showed that LRRK2 G2019S bound to and
phosphorylated Bcl-2 at Thr56, which resulted in a loss of the MMP
and led to p62/SQSTM1 association with the mitochondria, indicating
that Bcl-2 phosphorylation initiates excessive mitophagy. Thus, LRRK2
G2019S-induced Bcl-2 Thr56 phosphorylation might represent an
initiating point in the disruption of mitochondrial quality control, con-
tributing to cellular damage in PD relevant to the G2019S mutation.
2. Materials and method
2.1. Reagents and antibodies
Anti-Tom20, anti-Bcl-2, anti-HSP60, anti-GFP, anti-p62 antibodies
and protein A/G beads were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Anti-VDAC antibody was purchased from
Abcam (Cambridge, MA, USA). Human recombinant Bcl-2 protein
was purchased from Abnova (Taipei, Taiwan). Anti-LC3 and anti-
phosphorylated T56 Bcl-2 antibodies were purchased from Cell
Signaling Technology (Danvers, MA, USA). Anti-beta-actin antibody,
ammonium chloride (NH4Cl), Baﬁlomycin A1 (BFA), Acetyl Coenzyme
A, Oxaloacetic acid, 5,5′-dithiobis-2-nitrobenzoic acid (DTNB), cocktail
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chased from Sigma-Aldrich (St. Louis, MO, USA). LRRK2 antibody was
from Epitomics (Burlingame, CA, USA). Human recombinant LRRK2
and its mutant G2019S and D1994A, Tetramethylrhodamine (TMRM),
FITC-labeled goat anti-rabbit Abs, Hoechst 33342, and Lipofectamine®
2000 Transfection Reagent were purchased from Invitrogen (Carlsbad,
CA, USA). Lyso-ID Red dye was purchased from Enzo Life Sciences
(Farmingdale, NY, USA) and a Cathepsin enzyme assay kit was from
Biovision (Milpitas, CA, USA).
The LRRK2 (pDEST53-LRRK2-WT, plasmid 25044 [26]) and its mu-
tant (pDEST53-LRRK2-G2019S, plasmid 25045 [26]; pDEST53-LRRK2-
3XKD, plasmid 25049 [26]) expression vectors, pGFP-Bcl2 (plasmid
17999 [27]) and pGFP-Bcl2-Maob (plasmid 18001 [27]) were pur-
chased from Addgene (Cambridge, MA, USA). The T56A and T56D Bcl-
2 full-length site-directed mutants were constructed by a mutagenesis
reaction using a QuikChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA) and the pGFP-Bcl2 vector as template.2.2. Cell culture
Human cervix carcinoma cells HeLa were maintained in Dulbecco's
Modiﬁed Eagle Medium supplemented with 10% (v/v) heat-inactivated
fetal calf serum and 1% (v/v) penicillin/streptomycin.
LRRK2 G2019S patient ﬁbroblasts (PD1: ND29802 from 52-year-old
male PD patient; PD2: ND33879 from 66 year old female PD patient)
were purchased from Coriell Institute. Normal adult ﬁbroblast (HDFa)
was from Invitrogen. The ﬁbroblasts were maintained in Minimum
Essential Medium supplemented with 15% (v/v) heat-inactivated fetal
calf serum and 1% (v/v) penicillin/streptomycin.
Primary neurons from E18 rat midbrain tissue (BrainBits, Springﬁeld,
IL, USA) were seeded at about 50,000 cells on cover slides coated with
poly-D-lysine/laminin in neurobasal medium supplemented with 2%
B27 and 0.5 mM glutamate. At 7 DIV, cells were transfected with control
vector GFP, LRRK2 G2019S, Bcl-2T56A or Bcl-2T56D using Lipofectamine™
2000 Transfection Reagent combined with formulated BrainBits trans-
fection media for primary neurons (BrainBits, USA).
All cultured cells were maintained at 37 °C in 5% CO2–95% air.2.3. Isolation of mitochondrial-enriched fraction and lysate preparation
Themitochondriawere isolated as described previously [28]. Brieﬂy,
cells were washed with cold phosphate-buffered saline (PBS) and in-
cubated on ice in lysis buffer (250 mM sucrose, 20 mM HEPES-NaOH,
pH 7.5, 10mMKCl, 1.5mMMgCl2, 1mMEDTA, protease inhibitor cock-
tail, phosphatase inhibitor cocktail) for 30 min. Cells were scraped and
then disrupted 10 times by repeated aspiration through a 25 gauge
needle, followed by a 30 gauge needle. The homogenates were spun at
800 g for 10 min at 4 °C and the resulting supernatants were spun at
10,000 g for 20 min at 4 °C. The pellets were washed with lysis buffer
and spun at 10,000 g again for 20 min at 4 °C. The ﬁnal pellets were
suspended in lysis buffer containing 1% Triton X-100 and were noted
as mitochondrial-rich lysate fractions. The mitochondrial membrane
protein VDAC was used as marker and loading control.2.4. Immunocytochemistry
Cells were stained with antibodies against Tom20 (1:500) as d-
escribed previously [28]. To measure the membrane potential of mito-
chondria in cultures, cells were incubated with 0.25 μM TMRM for
20 min at 37 °C. To determine lysosomal activity, cells were incubated
with Lyso-ID Red dye for 30 min at 37 °C. The staining was imaged by
a microscope, and quantiﬁcation was carried out using NIH ImageJ
software.2.5. Citrate synthase activity assay
The cells were harvested, and 50 μg of lysate was added to each well
of 96-well plate containing 160 μL of assay buffer (60 mM Tris–HCl,
pH7.5, 200 μMAcetyl CoA, and 250 μMDTNB). The lysatewas incubated
for 5 min and then 20 μL of 2 mM oxaloacetate was added to each well.
OD was measured at 412 nm for 30 min using a spectrometry plate
reader. The rate of citrate synthase activity was quantiﬁed relative to
control cells.
2.6. Measurement of autophagic ﬂux
A difference in LC3 II levels in the presence and absence of
Baﬁlomycin A1 (BFA) represents autophagic ﬂux [29,30]; BFA prevents
maturation of autophagic vacuoles by inhibiting fusion between auto-
phagosomes and lysosomes. To assess the autophagic ﬂux, Hela cells
were transfected with LRRK2 WT and G2019S mutant and treated
with or without BFA (20 nM) for 2 h before cell harvest. Twenty-four
hours after transfection, total lysates were harvested and western
blots were performed. In patient ﬁbroblasts, cells were pretreated
with or without BFA (20 nM) for 2 h followed by western blot of total
lysates. LC3 II band intensities were normalized to β-actin. Autophagy
ﬂux was then evaluated by the difference in normalized LC3 II band
intensities with and without BFA treatment.
2.7. In vitro phosphorylation
Recombined human Bcl-2 (GST-tagged protein, 100 ng) was incu-
bated with 50 ng of recombined human LRRK2 (GST-tagged protein
consisting of amino acid residues 970–2527; either wild type, G2019S
mutant, or D1994A mutant) in 25 μL of reaction mixture (40 mM Tris–
HCl, pH7.5, 2 mM dithiothreitol, 10 mM MgCl2, and 100 μM ATP).
After incubation at 30 °C for 30min, the reactionwas stopped by boiling
in the sample-loading buffer for SDS-PAGE. The phosphorylation of Bcl-
2 was detected by anti-serine- and/or anti-threonine-phosphorylation
antibody.
2.8. Mass spectrometry analysis of phosphorylation site
Mass spectrometry analysis was performed in the Lerner Research
Institute Proteomics Laboratory, Cleveland Clinic. Brieﬂy, recombined
human Bcl-2 (GST-tagged protein, 500 ng) was incubated with 500 ng
of recombined human LRRK2 G2019S in 50 μL of reaction mixture
(40 mM Tris–HCl, pH7.5, 2 mM dithiothreitol, 10 mM MgCl2, and
100 μMATP). The reactionmixturewas subjected to SDS-PAGE followed
by Commassie blue staining. For the protein digestion, the bands of Bcl-
2were cut tominimize excess polyacrylamide, divided into a number of
smaller pieces. The gel pieces washed with water and dehydrated in
acetonitrile. The bands were then reduced with DTT and alkylated
with iodoacetamide prior to the in-gel digestion. All bands were
digested in-gel using trypsin, by adding 5 μL 10 ng/μL trypsin in
50 mM ammonium bicarbonate and incubating overnight digestion
at room temperature to achieve complete digestion. The peptides
that were formed were extracted from the polyacrylamide in two
aliquots of 30 μL 50% acetonitrile with 5% formic acid. These extracts
were combined and evaporated to b10 μL in Speedvac and then re-
suspended in 1% acetic acid to make up a ﬁnal volume of ~30 μL for
LC-MS analysis.
The LC-MS system was a Finnigan LTQ-Obitrap Elite hybrid mass
spectrometer system. The HPLC column was a Dionex 15 cm × 75 μm
id Acclaim Pepmap C18, 2 μm, 100 Å reversed phase capillary chroma-
tography column. Five μL volumes of the extract were injected and the
peptides eluted from the column by an acetonitrile/0.1% formic acid
gradient at a ﬂow rate of 0.25 μL/min were introduced into the source
of the mass spectrometer on-line. The microelectrospray ion source is
operated at 2.5 kV. The digest was analyzed using the data dependent
Fig. 1. LRRK2 G2019S causes mitochondrial depolarization and a loss of mitochondrial mass. (A) PD ﬁbroblasts with the LRRK2 G2019S mutant were stained with 0.25 μM TMRM. The
ﬂuorescent density of TMRMwas expressed asmean±S.D. from three independent experiments. At least 200 cells/groupwere counted. PD1:ND29802 from52-year-oldmale PDpatient;
PD2: ND33879 from 66-year-old female PD patient. Normal ﬁbroblast (Nor): HDF from a normal adult. (B) PD patient ﬁbroblasts were stained with anti-Tom20 antibody (Tom20: a
mitochondrialmarker, red) andDAPI (nuclear, blue). Theﬂuorescent density of Tom20was expressed asmean±S.D. from three independent experiments. (C) Activity of citrate synthase
(CS) that reﬂects mitochondrial mass was determined using total cell lysates of PD patient ﬁbroblasts. The activity of CS was calculated and expressed as mean ± S.D. from three
independent experiments. (D) Autophagic ﬂux in PD ﬁbroblasts was determined by quantiﬁcation of LC3 II degradation rate via treatment with or without BFA (20 nM). The data
were expressed asmean±S.D. from three independent experiments. *pb 0.05 versusnormalﬁbroblasts. (E)HeLa cellswere transfectedwith LRRK2 or G2019S. Activity of citrate synthase
(CS) was determined at the indicated groups. The CS activity was calculated and expressed as mean ± S.D. from three independent experiments. (F) HeLa cells were transfected with
LRRK2 G2019S. Cells were treated with autophagy inhibitor BFA (20 nM) and NH4Cl (5 mM) for 4 h and then stained with Tom20 (green) and DAPI (blue). The ﬂuorescent density of
Tom20 was expressed as mean ± S.D. from three independent experiments. *p b 0.05 versus non-transfected mock control, # p b 0.05 versus cells with G2019S alone. At least 200
cells/group were counted. Scale bar is 10 μm.
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to determine peptide molecular weights and product ion spectra to de-
termine amino acid sequence in successive instrument scans. Thismode
of analysis produces approximately 15,000 collisionally induced disso-
ciation (CID) spectra of ions ranging in abundance over several orders
of magnitude. Please note that not all CID spectra are derived from
peptides.
The data were analyzed by using all CID spectra collected in the ex-
periment to search the rodent reference sequence database using Mas-
cot. All matching spectra were veriﬁed by manual interpretation. The
interpretation process was aided by additional searches using the pro-
grams Sequest and Blast as needed.2.9. Generation of stable cell line
Cells constitutively expressing GFP or GFP-Bcl-2 or GFP-Mito-Bcl-2
were obtained by transfection of HeLa cells with the pGFP or pGFP-
Bcl-2 or pGFP-Bcl-2-Maob vectors, respectively, and selection with
G418 (1 mg/mL).2.10. Western blot analysis
Protein concentrationswere determined by Bradford assay. Proteins
(30 μg) were resuspended in Laemmli buffer, loaded on SDS-PAGE and
Fig. 2.p62 is required for LRRK2G2019S-induced excessivemitophagy. (A)HeLa cellswere transfectedwith G2019S.Mitochondrial fractionswere isolated 16h after transfection, and p62
levels were detected bywestern blot with anti-p62 antibody. VDACwas used as a mitochondrial loading control. Lower: p62 level on themitochondria was quantitated and expressed as
mean± S.D. from three independent experiments. *p b 0.05 versus non-transfectedmock group. HeLa cells were co-transfectedwith G2019S and control siRNA (con siRNA) or p62 siRNA
as indicated. (B) Left: Total levels of p62were detected bywestern blot analysis with the indicated antibodies. Actinwas used as a loading control. Right top: Cells were stained with anti-
Tom20 antibody (green) and DAPI (nuclear, blue). The ﬂuorescent density of Tom20 was expressed as mean ± S.D. from three independent experiments (right bottom). (C) Cells were
stainedwith Lyso-ID Red dye. The ﬂuorescent density of lyso-ID Red dye that indicates lysosome activity was expressed asmean± S.D. from three independent experiments. At least 200
cells/group were counted. Scale bar is 10 μm. (D) Enzyme activity of lysosomal protein Cathepsin B was measured by a Cathepsin B assay kit to further assess lysosomal activity. The data
were expressed as mean ± S.D. from three independent experiments. *, p b 0.05 vs. control group; #, p b 0.05 vs. LRRK2 G2019S-expressing cells treated with control siRNA (consiRNA).
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with the indicated antibody, followed by visualization by ECL.
3. Results
3.1. Concomitant occurrence of mitochondrial depolarization and
mitochondrial mass loss in cells expressing LRRK2 G2019S
Primary ﬁbroblasts from PD patients carrying the disease-associated
mutations have been used as a cell culture model to observe mitochon-
drial phenotypes associated with PD [12,13,15]. In two lines of PD
patient dermal ﬁbroblasts carrying the LRRK2G2019Smutation, we ob-
served a dramatic loss of themitochondrialmembrane potential (MMP)
when compared with that in normal ﬁbroblasts (Fig. 1A), which is con-
sistent with previous studies [12,31]. Moreover, by either staining cells
with Tom20, a mitochondrial outer-membrane protein, or measuring
citrate synthase activity, which reﬂects mitochondrial mass [32,33],
we found a signiﬁcant loss in mitochondrial mass in these PD patient
ﬁbroblasts, as evidenced by a decrease in the ﬂuorescent density of
Tom20 and a lower activity of citrate synthase (Fig. 1B and C). These
aberrant mitochondrial events were accompanied by an increase inautophagic ﬂux (Fig. 1D), which denotes the dynamic process of au-
tophagy and is a more reliable indicator of autophagic activity [34].
Thus, an endogenous LRRK2 G2019S mutation might accelerate the
process of autophagy. Given that depolarizedmitochondria are selected
for elimination via mitophagy [35,36], we speculated that the loss of
mitochondrial mass in PD patient ﬁbroblasts with the G2019Smutation
is due to excessive mitophagy.
In parallel, we determined mitochondrial mass loss in HeLa cells
in which either LRRK2 WT or the G2019S mutant was expressed.
Consistent with the ﬁndings in PD patient ﬁbroblasts (Fig. 1C), the
activity of citrate synthase was signiﬁcantly decreased in both
LRRK2 WT- and G2019S-expressing HeLa cells, which was corrected
by treatment with Baﬁlomycin A1 [BFA, inhibits autophagy either by
blocking autophagosome–lysosome fusion, or by blocking lysosomal
degradation] (Fig. 1E). Further, the ﬂuorescent density of Tom20was
reduced in LRRK2 G2019S mutant-expressing HeLa cells, which was
corrected by treatment with either BFA or NH4Cl (ammonium chlo-
ride, an inhibitor to inhibit lysosome activity) (Fig. 1F). Together,
the above data showed that either endogenous or exogenous expres-
sion of the LRRK2 G2019S mutation caused mitochondrial mass loss.
Because of higher transfection efﬁciency, in the following study, we
Fig. 3. Bcl-2 is a key factor for LRRK2 G2019S-induced excessivemitophagy. (A) Total levels of Bcl-2 in PD patient ﬁbroblasts were determined bywestern blot. Actinwas used as a loading
control. Histogram: protein level of Bcl-2was quantitated and expressed asmean±S.D. from three independent experiments. *p b 0.05 versus normalﬁbroblast (Nor). (B) HeLa cellswere
transfected with LRRK2 or G2019S or 3XKD (kinase dead mutant). Bcl-2 protein level was detected by anti-Bcl-2 antibody 20 h after transfection. Actin was used as a loading control.
Histogram: level of Bcl-2 was quantitated and expressed as mean ± S.D. from three independent experiments. *p b 0.05 versus non-transfected mock control. (C) Top: expression of
GFP, GFP-Bcl-2 (Bcl-2) and GFP-M-Bcl-2 (M-Bcl-2) in the stable HeLa cells were detected by western blot using anti-GFP antibody. Actin was used as a loading control. Bottom: GFP or
Bcl-2 or M-Bcl-2 stable HeLa cells were transfected with G2019S. Cells were stained with TMRM 20 h after transfection. The ﬂuorescent density of TMRM was expressed as mean ±
S.D. from three independent experiments. *p b 0.05 versus non-transfected GFP control; #p b 0.05 versus control GFP cells transfected with G2019S. (D) Mitochondrial fractions in the
indicated stable cells were isolated 20 h after transfection with LRRK2 G2019S. p62 level on the mitochondria was detected by western blot analysis; VDAC was used as a mitochondrial
loading control. Mitochondrial p62 level was expressed as mean ± S.D. from three independent experiments. *p b 0.05 versus control GFP cells. (E) LC3 II was detected by anti-LC3
antibody in the indicated stable cell lines 24 h after transfection with LRRK2 G2019S. Autophagic ﬂux was calculated in the presence or absence of BFA and expressed as mean ± S.D.
from three independent experiments. *p b 0.05 versus non-transfected GFP control; #p b 0.05 versus control GFP cells with G2019S. (F) The activity of citrate synthase (CS) was
determined as above. The activity of CS was expressed as mean ± S.D. from three independent experiments. *p b 0.05 versus non-transfected GFP control; #p b 0.05 versus control
GFP cells with G2019S.
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to determine potential molecular mechanism by which LRRK2
G2019S induces loss of mitochondrial mass.
3.2. P62/SQSTM1 is implicated in LRRK2 G2019S-induced
excessive mitophagy
SQSTM1/p62 is a bridging protein between the ubiquitinated pro-
teins/structures and the autophagosome component LC3 II [50].
Recruitment of STSTM1/p62 to themitochondrial clusters has been con-
sidered to be an essential step for mitophagy [37]. Next, we determined
whether p62 is involved in the mitophagic process induced by LRRK2G2019S. Western blot of subcellular fractionations revealed that p62
translocated to the mitochondria in response to expression of LRRK2
WT and that this translocation was much enhanced in cells with the
G2019S mutant (Fig. 2A). Next, we reduced the protein level of p62 by
RNA interference (siRNA) and determined the mitochondrial mass
and lysosomal activity. Down-regulation of p62 level corrected LRRK2
G2019S-induced mitochondrial mass loss (Fig. 2B) and suppressed
G2019S-induced lysosome hyperactivity as demonstrated by a decrease
in lyso-ID ﬂuorescent density and a lower enzyme activity of lysosomal
Cathepsin B (Fig. 2C and D). Collectively, the above data indicate that
the LRRK2 G2019S mutant causes excessive mitophagy likely via p62-
mediated mitochondrial degradation.
Fig. 4. LRRK2G2019S bound to andphosphorylated Bcl-2 at Thr56. (A) Recombinant humanGST-Bcl-2was incubatedwith recombinantWT andmutant LRRK2 in in vitro phosphorylation
buffer. Phosphor-LRRK2 and phosphor-Bcl-2were detected bywestern blot analysiswith amixture of anti-phosphor-serine/threonine antibodies. (B) The phosphorylation site of Bcl-2 by
LRRK2 G2019S was analyzed by mass spectrometry analysis performed by Lerner Research Institute Proteomics Laboratory in Cleveland Clinic. The SRM (selective reaction monitoring)
analyses of both the tryptic and the chymotryptic protein digestion determined that Thr56 of Bcl-2 is a phosphorylation site by G2019S. Shown is the result from SRM analysis of the
chymotryptic protein digestion. (C) HeLa cells were transfected with LRRK2 or G2019S or 3XKD (kinase dead mutant). Phosphor-Bcl-2 was detected by anti-phosphor-Thr56-Bcl-2
antibody. Phosphor-Bcl-2 was quantitated and expressed as mean ± S.D. from three independent experiments. *p b 0.05 versus non-transfected control cells. (D) Recombinant human
GST-Bcl-2was incubatedwith recombinantmutant LRRK2 (G2019S). The phosphor-Bcl-2 was detected by IBwith anti-phosphor-Thr56-Bcl-2 antibody. (E) Total lysates of PD ﬁbroblasts
were harvested. Phosphor-Bcl-2 was detected by anti-phosphor-Thr56-Bcl-2 antibody. Phosphor-Bcl-2 was quantitated and expressed as mean ± S.D. from three independent
experiments. *p b 0.05 versus normal ﬁbroblast (Nor).
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In this study, we found that the MMP was decreased in LRRK2
G2019S PD patient ﬁbroblasts (Fig. 1A). Bcl-2 plays a critical role in
maintaining the MMP. The protein level of Bcl-2 was dramatically de-
creased in two lines of PD patient ﬁbroblasts carrying the LRRK2
G2019S mutant (Fig. 3A) and in HeLa cells expressing with either
LRRK2 WT or the G2019S mutant (Fig. 3B). However, the protein level
of Bcl-2 was not signiﬁcantly altered in cells expressing the LRRK2
3XKD mutant (LRRK2 kinase-dead mutant), suggesting that the de-
crease in Bcl-2 protein level might be due to LRRK2 kinase activity.
Given that Bcl-2 has the dual function of inhibition of autophagy and
maintenance of the MMP [21,22,24], we next asked whether Bcl-2 is
involved in LRRK2 G2019S-induced excessive mitophagy.
To test this hypothesis, we generated stable HeLa cell lines express-
ing GFP, GFP-Bcl-2, or speciﬁc mitochondrial targeting GFP-Bcl-2 (GFP-
M-Bcl-2). We found that LRRK2 G2019S-induced loss of the MMP was
recovered in both GFP-Bcl-2 and GFP-M-Bcl-2 stable cells (Fig. 3C—
lower panel). Moreover, the G2019S-induced p62 translocation to the
mitochondria was greatly reduced in both GFP-Bcl-2 and GFP-M-Bcl-2
stable cells, when compared with that in control GFP stable cells with
the G2019S (Fig. 3D). Further, increased autophagic ﬂux and decreased
mitochondrial mass induced by the G2019S mutant were corrected inboth GFP-Bcl-2 and GFP-M-Bcl-2 stable cells (Fig. 3E and F). Taken
together, these data demonstrated that Bcl-2 is an important element
in LRRK2 G2019S-caused excessive mitophagy. However, the mecha-
nism of LRRK G2019S-induced downregulation of Bcl-2 remains to be
determined.
3.4. LRRK2 G2019S binds to and phosphorylates Bcl-2 at Threonine 56
The function of Bcl-2 is regulated by post-translational modiﬁcation,
such as phosphorylation [38]. LRRK2 is a serine–threonine kinase and its
mutant G2019S augments its kinase activities [10]. Given that Bcl-2
alteration is dependent on LRRK2 kinase activity (Fig. 3B), we next
examined the possibility that Bcl-2 could be phosphorylated by
LRRK2. Recombinant human Bcl-2 (GST-tagged protein) was subjected
to an in vitro kinase assay by incubating with recombinant human
LRRK2 (GST-tagged wide-type, G2019S mutant, and D1994A mutant
(kinase dead) protein consisting of all the functional domains [amino
acid residues 970–2527]). In addition to auto-phosphorylation of both
LRRK2 WT and the G2019S mutant, we found that the G2019S mutant
predominantly phosphorylated Bcl-2 protein at serine/threonine
residues whereas the D1994 showed an inability to phosphorylate it
(Fig. 4A). Mass spectrometry analysis further revealed one conserved
site, Thr56, which was phosphorylated by LRRK2 G2019S (Fig. 4B).
Fig. 5. Bcl-2 Thr56 phosphorylation is required for LRRK2 G2019S-induced mitochondrial depolarization and excessive mitophagy. HeLa cells were co-transfected with G2019S and the
indicated plasmids. (A) Cells were stained with TMRM 20 h after transfection. The ﬂuorescent density of TMRM was expressed as mean ± S.D. from three independent experiments.
*p b 0.05 versus non-transfectedmock control; #p b 0.05 versus control GFPwith G2019S. (B) LC3 II was detected by anti-LC3 antibody 24 h after transfection. Actin was used as a loading
control. Level of LC3 II was quantitated and expressed as mean ± S.D. from three independent experiments. *p b 0.05 versus control GFP cells with G2019S. (C) Upper panel: cells were
stained with Lyso-ID Red dye. The ﬂuorescent density of Lyso-ID dye was quantitated. At least 200 cells/group were counted. Lower panel: enzyme activity of lysosomal Cathepsin B was
measured. The datawere expressed asmean± S.D. from three independent experiments. (D) The activity of citrate synthase (CS)was determined as above. The CS activitywas calculated
and expressed as mean ± S.D. from three independent experiments. *p b 0.05 versus non-transfected mock control; #p b 0.05 versus control GFP with G2019S.
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we conﬁrmed that Bcl-2 was phosphorylated at this site by LRRK2
G2019S (Fig. 4C). There was no signiﬁcant Thr56 phosphorylation of
Bcl-2 observed in cells expressing with either LRRK2 WT or 3XKD
(Fig. 4C). The Thr56 phosphorylation of Bcl-2 was also greatly increased
in vitro when recombinant protein Bcl-2 was incubated with LRRK2
G2019S recombinant protein (Fig. 4D). Finally, increased Thr56 phos-
phorylation of Bcl-2 was observed in the two LRRK2 G2019S PD patientﬁbroblast lines (Fig. 4E). Thus, we concluded that Bcl-2 is a target of
LRRK2 G2019S for phosphorylation.
3.5. Thr56 phosphorylation of Bcl-2 promotes excessive mitophagy
To determine the functional importance of Bcl-2 Thr56 phosphoryla-
tion in mitochondrial damage, we generated a Thr56 to alanine (Ala)
mutant (Bcl2T56A, non-phosphorylated) and to aspartic acid (Asp)
Fig. 6. Abolishment of Bcl-2 Thr56 phosphorylation corrected mitochondrial mass loss and reduced neurite loss of primary dopaminergic neurons expressing G2019S. Primary rat DA
neurons (cultured for 7 days) were transfected with the indicated plasmids for 3 days. (A) Neurons were stained with anti-Tom20 antibody (red) to determine mitochondrial mass.
Histogram showed the ﬂuorescent density of Tom20 (Mean ± S.D. from three independent experiments). (B) Neurons were stained with anti-TH antibodies (red). Neurite length was
measured with NIH ImageJ software and expressed as Mean ± S.D. from three independent experiments. Scale bar is 10 μm. At least 60 neurons/group were counted. *p b 0.05 versus
non-transfected control cells; #p b 0.05 versus control GFP with G2019S.
19Y.-C. Su et al. / Biochimica et Biophysica Acta 1852 (2015) 12–21mutant (Bcl-2T56D, phosphomimetic) of Bcl-2. In HeLa cells co-
expressing with either Bcl-2WT or Bcl-2T56A, the G2019S-induced
loss of MMP was corrected (Fig. 5A). However, phosphomimetic
Bcl-2 (Bcl-2T56D) did not prevent the LRRK2 G2019S-induced MMP
reduction (Fig. 5A). These data suggest that Bcl-2 Thr56 phospho-
rylation is required for G2019S-induced mitochondrial depola-
rization. Further, in cells co-overexpressing LRRK2 G2019S with
Bcl-2WT or Bcl-2T56A, a reduction of G2019S-induced conversion of
LC3 from form I to form II, a marker of autophagy [39], was observed
(Fig. 5B). Moreover, lysosome hyperactivity was completely
abolished by expression of either Bcl-2WT or Bcl-2T56A in LRRK2
G2019S-expressing cells (Fig. 5C). Concomitantly, the decrease in
mitochondrial mass caused by the G2019S mutant was rescued by
either Bcl-2WT or Bcl-2T56A expression (Fig. 5D). Collectively, our
ﬁndings showed that Thr56 phosphorylation of Bcl-2 is required for
LRRK2 G2019S-induced mitochondrial depolarization and mito-
chondrial mass loss.
3.6. Thr56 phosphorylation of Bcl-2 caused neurite shortening in rat
primary dopaminergic neurons expressing LRRK2 G2019S
Mouse cortical neurons expressing LRRK2 G2019S mutation
displayed autophagic degradation of mitochondria and dendriteshortening [40]. LRRK2 G2019S expression in human neuroblastoma
SH-SY5Y cells led to decrease in neurite length in association with
increases in autophagic vacuoles [41]. These lines of evidence sug-
gest an implication of aberrant mitophagy in neurodegeneration.
Next, we examined the impact of Bcl-2 Thr56 phosphorylation on
mitophagy in dopaminergic (DA) neurons expressing LRRK2 G20
19S. Primary rat midbrain DA neurons were co-expressed with
LRRK2 G2019S with either Bcl-2T56A or Bcl-2T56D. Consistent with
our ﬁndings above, we observed a great reduction of mitochondrial
mass in LRRK2 G2019S-expressing DA neurons; however, co-
expression of Bcl-2T56A corrected this aberrant event (Fig. 6A). Fur-
ther, we stained neurons with anti-tyrosine hydroxylase (TH) anti-
body (a marker of DA neuron) to determine the neurite length of
DA neurons. LRRK2 G2019S-expressing DA neurons exhibited
shorter and fewer neurites, which is consistent with previous reports
[41]. By contrast, co-expression of Bcl-2T56A signiﬁcantly improved
neuronal morphology; the neurite length of DA neurons was in-
creased from 28 to 86% relative to that in control vector-expressing
neurons (Fig. 6B). Taken together, the above data conﬁrm our ﬁnd-
ings that Bcl-2 Thr56 phosphorylation is required for LRRK2
G2019S-induced excessive mitophagy. Importantly, Bcl-2 Thr56
phosphorylation might be implicated in LRRK2 G2019S-induced
neurodegeneration.
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In this study, we have conﬁrmed that the LRRK2 G2019Smutation
caused mitochondrial damage and exacerbated mitophagy. Impor-
tantly, we provide evidence that these aberrant events are, at least
in part, mediated by Bcl-2 Thr56 phosphorylation caused by the
G2019S mutation.
Bcl-2 can be regulated by post-translational modiﬁcation by phos-
phorylation, dimerization, and proteolytic cleavage [38,42,43]. Bcl-2 is
the target of a number of kinases, andmultiple conformational changes
are expected, depending on the number and location of the phosphory-
lation residues. Phosphorylation of Bcl-2 induced a strong inhibition of
anti-apoptotic potential by some kinases, including Raf-1 kinase and
MAPK [44,45]. Moreover, Bcl-2 phosphorylation by JNK and p38 MAPK
is associated with a decrease in the anti-apoptotic potential of Bcl-2
via loss of MMP, release of cytochrome c, and activation of caspases
[45,46]. Thus, Bcl-2 phosphorylationmight alter the stability of this pro-
tein, signaling for mitochondrial impairment and cellular damage,
although the detailed transduction pathway is not yet clear. In this
study, we report for the ﬁrst time that LRRK2 interacted with Bcl-2 di-
rectly and that the G2019S mutant speciﬁcally phosphorylated Bcl-2
at Thr56 residue. The importance of Bcl-2 Thr56 phosphorylation was
further supported by the ﬁndings that a site-directed mutant, Bcl-
2T56A (non-phosphorylated), reversed the G2019S-induced mitochon-
drial depolarization and blocked mitochondrial mass loss. As another
line of evidence, stable expression of either Bcl-2 wild-type (Bcl-2) or
a mitochondrial targeting Bcl-2 (M-Bcl2) not only maintained the
MMP but also corrected the G2019S-induced elevated autophagic ﬂux
andmitochondrialmass loss. Thus,we propose that Thr56 phosphoryla-
tion of Bcl-2 by LRRK2 G2019S might be a crucial step of mitochondrial
disorder, which initiates the subsequent cellular damage in the context
of PD relevant to G2019S.
Several lines of evidence show that the dysfunctional mitochondria
and disrupted autophagy are co-exhibited in patientﬁbroblasts carrying
the LRRK2 G2019S mutant and primary neurons overexpressing
LRRK2 G2019S [16,41,47,48]. Moreover, transgenic mice expressing
the LRRK2-G2019S mutation show mitochondrial alterations together
with excessive mitophagy [18]. Thus, decreased membrane potential
caused by Bcl-2 Thr56 phosphorylation in cells expressing the LRRK2
G2019S mutation, may cause mitochondrial damage and exacerbate
mitophagy, which in turn leads to increased mitochondrial clearance.
In this study, we found increased mitophagy in cells with LRRK2
G2019S, which was accompanied by mitochondrial depolarization,
recruitment of p62 to the mitochondria, increased LC3II levels and
lysosomal activity. Parkin recruitment to the depolarized mitochondria
induced by the protonophore carbonyl cyanide m-chlorophenyl hydra-
zone (CCCP) promotes ubiquitination of mitochondrial outer mem-
brane proteins, and induces mitophagy [49]. The involvement of p62
in Parkin-related mitophagy is controversial [37,50,51]. Given that
HeLa cells do not express Parkin, in our study, LRRK2 G2019S-
induced mitochondrial mass loss might be independent of Parkin-
related mitophagy. Instead, p62 might play an active role in LRRK2
G2019S-induced mitochondrial degradation; downregulation of
p62 corrected mitochondrial mass loss and lysosomal hyperactivity
in the presence of LRRK2 G2019S. In addition, previous studies
showed that mitochondrial biogenesis modulates mitochondrial
mass in cardiac hypertrophy [52] and renal ischemia–reperfusion in-
jury [53]. Thus, it remains to be determined as to whether LRRK2
G2019-induced loss of mitochondrial mass is due to lower activity
of mitochondrial biogenesis.
In summary, in this study, we demonstrated that LRRK2 G2019S
caused mitochondrial mass loss, at least in part, through phosphoryla-
tion of Bcl-2 at Thr56. Thus, our ﬁndings provide new insight into the
mechanism by which LRRK2 G2019S causes mitochondrial disorder
and cellular damage, revealing a potential therapeutic target to prevent
G2019S-induced neurodegeneration.Acknowledgement
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